Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021


HomeGenieMD Inc.GenieMD Offers Remote Colorectal Cancer Screening

GenieMD Offers Remote Colorectal Cancer Screening

Remote Colorectal Cancer Screening

It is a well-established fact that early detection of colorectal cancer dramatically increases the odds of survival. Unfortunately, the Covid-19 pandemic kept many people from undergoing planned colorectal cancer screening exams in 2020.

During Colorectal Cancer Awareness Month this March, global telehealth provider GenieMD and its medical group encourage all eligible adults to take advantage of new technologies that permit reliable at-home colorectal cancer screening exams.

In 2020, there were an estimated 104,610 new cases of colorectal cancer in the United States, and approximately 53,000 deaths, according to the American Cancer Society. While predominantly affecting adults over the age of 50, growing numbers of younger people are being diagnosed. Those diagnosed with localized disease have a 90% five-year survival rate. But that number declines to just 14% for those who are diagnosed after the disease has significantly spread.

“Colorectal cancer is the number two cause of cancer death in the United States, trailing only lung; but it’s preventable,” said GenieMD medical group physician David Ross, MD. “Colon cancer grows from a precancerous polyp over time, so if precancerous polyps are detected and removed, colon cancer cannot develop.”

Colonoscopy, an in-person procedure that permits a physician to visualize the colon and remove polyps using an endoscope, is the gold standard for colon cancer screening. However, it requires a laxative preparation, a day off from work, and a visit to the hospital or surgery center, which many patients are hesitant to do. Dr. Ross notes that next generation at-home tests are highly accurate and may be an excellent substitute for any patient who is hesitant about having a colonoscopy.

Dr. Ross recommends the Cologuard at-home screening test for individuals at average risk for colorectal cancer. That includes those over the age of 45 who do not have a first degree relative or a personal history of colorectal cancer. It is not recommended for people who have had pre-cancerous polyps in the past; they are considered to be at higher than average risk.

“Cologuard involves an easy-to-use stool test at home,” said Dr. Ross. “A negative test predicts that there are no significant polyps or tumors.” After a negative Cologuard test, patients should be re-screened in three years. A positive Cologuard finding does not mean that the patient has colorectal cancer; it simply indicates that a colonoscopy is necessary as a follow-up procedure.

GenieMD medical group physicians are licensed in all states across the US and are able to prescribe the most appropriate colorectal cancer screening test, either an in-person colonoscopy or at-home test, for each patient, depending upon underlying risk factors, personal and family history.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy